Intravitreal conbercept injection for neovascular age-related macular degeneration

To evaluate the efficacy and safety of intravitreal injection of conbercept in patients with neovascular age-related macular degeneration (AMD). Retrospective review of 66 eyes of 63 patients with neovascular AMD. All patients received 0.5 mg intravitreal injections of conbercept monthly for 3 conse...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of ophthalmology Vol. 12; no. 2; pp. 252 - 257
Main Authors Wu, Bing-Hui, Wang, Bing, Wu, Hui-Qin, Chang, Qin, Lu, Hui-Qin
Format Journal Article
LanguageEnglish
Published China International Journal of Ophthalmology Press 18.02.2019
Press of International Journal of Ophthalmology (IJO PRESS)
Subjects
Online AccessGet full text
ISSN2222-3959
2227-4898
DOI10.18240/ijo.2019.02.11

Cover

Loading…
More Information
Summary:To evaluate the efficacy and safety of intravitreal injection of conbercept in patients with neovascular age-related macular degeneration (AMD). Retrospective review of 66 eyes of 63 patients with neovascular AMD. All patients received 0.5 mg intravitreal injections of conbercept monthly for 3 consecutive months, and then treatment was performed. The changes of best-corrected visual acuity (BCVA) and central macular thickness (CMT) were observed before and after treatments. Minimum follow-up time was 12mo. SPSS 22.0 statistical software was used for statistical analysis. The mean BCVA and CMT of 66 eyes (63 patients) were 1.11±0.60, 533.20±219.95 µm at baseline, and were 0.68±0.38, 310.28±125.60 µm at 3mo. No subjects were lost during the first three months, the improvements were all significantly ( <0.05). During the whole follow-up time of 12mo, 15 subjects (18 eyes) were lost. The mean BCVA and CMT of the rest 48 eyes with the follow-up time at least 1y were 0.83±0.46 and 547.59±196.77 µm at baseline, after 3mo and 12mo of conbercept injections became 0.55±0.41, 318.24±141.29 µm and 0.55±0.51, 333.87±173.25 µm. The differences were significant ( <0.05). No serious complications were observed. Intravitreal injection of conbercept appears to significantly improve visual acuity and anatomical outcomes in patients with neovascular AMD, no serious adverse reactions and complications are observed.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Co-first authors: Bing-Hui Wu and Bing Wang
ISSN:2222-3959
2227-4898
DOI:10.18240/ijo.2019.02.11